This study is investigating how a special imaging agent, [18F]PI-2620, binds to tau protein in the brains of people with Parkinson's disease (PD), including those with sporadic PD and a genetic form called LRRK2 PD. Researchers will use a high-resolution PET (positron emission tomography) scanner, called NeuroEXPLORER, to take pictures of the brain. The main goal is to compare the amount of tau binding in different groups, measured by a value called SUVr, during a single PET scan. This study aims to enroll 60 participants between 45 and 85 years old. The current recruitment status is unclear.

Study design

This is an interventional study planning to enroll 60 participants. It will compare tau binding in different groups, including those with Parkinson's disease, other neurological conditions, and healthy volunteers.

What's involved

Participants will undergo PET imaging using the [18F]PI-2620 tracer once. Some participants may have a follow-up imaging scan 12 months later.

Compensation

Not stated in the trial record.

Follow-up

Some participants recruited in the first year will have a repeat imaging scan at 12 months to investigate changes in tau pathology.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.